Companies / Evident Vascular

Medical device company profile

Evident Vascular

San Jose device company developing an intravascular ultrasound guidance platform and catheters for vascular intervention.

Medical Device Manufacturer and DeveloperCardiovascular & Vascular

Headquarters🇺🇸San Jose, California, United States

Founded2021

Commercial statusIn developmentIntravascular ultrasound platform in development; not available for sale.

Employees11–50 ^[1]LinkedIn company-size range · Checked 2026-11-04

Estimated revenueNot confirmed

Disclosed fundingUS$35 million ^[5]Series A announced October 2023; a subsequent March 2025 Series B had no disclosed amount.

Official websiteevidentvascular.com ↗

Company overview

Evident Vascular is a San Jose, California medical device company developing intravascular ultrasound technology for image-guided vascular intervention. Founded in 2021, it is led by CEO and co-founder Howard Rosen.

The company’s planned offering combines the Evident Vascular Guidance System with intravascular imaging catheters. Its development programme focuses on peripheral vascular procedures, with AI-assisted image processing and workflow tools intended to help clinicians interpret images during treatment.

Evident emerged from stealth in October 2023 with a US$35 million Series A led by Vensana Capital and announced a subsequent Series B in March 2025 without disclosing its size. Its imaging platform remains in development and is not available for sale in the United States or other jurisdictions.

^{[1][2][3][4][5][6]}

Leadership

5 people

Howard RosenChief Executive Officer & Co-founder ^[3]

Danielo PiazzaChief Product Officer & Co-founder ^[3]

Patrick Phillips, PhDChief Technology Officer & Co-founder ^[3]

Paul ChanChief Financial Officer ^[3]

Virgil AguirreVice President, Manufacturing Operations ^[3]

Products & regulatory status How does MedTechIndex get this information?

Summary

Evident states that its vascular guidance system and catheters are in development and are not available for sale in the United States or any other jurisdiction. The platform’s peripheral vascular applications and AI-assisted imaging features remain development objectives. ^[2][4]